NexGel terminates CEO Adam Levy, appoints Brian Kieser interim CEO, launches strategic review

NEXGEL, INC.

Adam R. Levy terminated as CEO without cause effective Aug 21, 2026; resigned from board and all officer positions.
Brian Kieser appointed Interim CEO effective Aug 21, 2026; is CEO of Fountainhead Lifesciences and board member since May 6, 2026.
Board formed Special Committee for Strategic Review and Value Creation (Kevin Harris, Chair; Steve Glassman) to assess operations.
Committee authorized to evaluate divestiture, partnerships, restructuring or wind-down of non-core assets; initial framework expected in 30-45 days.
Levy to provide 90-day transition assistance; Separation Agreement terms not yet finalized, with 8-K amendment to follow.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Adam R. Levy

Director

NXGL · NEXGEL, INC.

Effective: 2026-08-21
Filed: August 21, 2026, 4:42 PM ET

Mr. Levy resigned from the Company’s Board of Directors

Appointed (interim)

Brian Kieser

Interim Chief Executive Officer

NXGL · NEXGEL, INC.

Effective: 2026-08-21
Filed: August 21, 2026, 4:42 PM ET

Effective as of the Separation Date, the Board appointed Brian Kieser to serve as Interim Chief Executive Officer of the Company.

Departed

Adam R. Levy

Chief Executive Officer

NXGL · NEXGEL, INC.

Effective: 2026-08-21
Successor: Brian Kieser
Filed: August 21, 2026, 4:42 PM ET

Effective August 21, 2026 (the “ Separation Date ”), NexGel, Inc. (the “ Company ”) terminated Adam R. Levy’s employment as Chief Executive Officer without Cause (as defined in Mr. Levy’s Executive Employment Agreement, dated July 23, 2026), and Mr. Levy resigned from the Company’s Board of Directors (the “ Board ”) and from all other officer, director, committee and fiduciary positions held by him with the Company and its subsidiaries.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Adam R. Levy resigned as Director at NEXGEL, INC..

Action: resigned
Role: Director

Exact text from the filing

Mr. Levy resigned from the Company’s Board of Directors

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Kieser was appointed as Interim Chief Executive Officer at NEXGEL, INC..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

Effective as of the Separation Date, the Board appointed Brian Kieser to serve as Interim Chief Executive Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Adam R. Levy was terminated as Chief Executive Officer at NEXGEL, INC..

Action: terminated
Role: Chief Executive Officer

Exact text from the filing

Effective August 21, 2026 (the “ Separation Date ”), NexGel, Inc. (the “ Company ”) terminated Adam R. Levy’s employment as Chief Executive Officer without Cause (as defined in Mr. Levy’s Executive Employment Agreement, dated July 23, 2026), and Mr. Levy resigned from the Company’s Board of Directors (the “ Board ”) and from all other officer, director, committee and fiduciary positions held by him with the Company and its subsidiaries.

View on SEC.gov

NEXGEL, INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-039708

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.